ATAXIA MARKET ANALYSIS

Ataxia Market, by Treatment Type (Pharmacotherapy (Levodopa, Pramipexole, Desvenlafaxine, Venlafaxine, and Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)), Physical Therapy, Speech Therapy, and Others (Adaptive Devices and Occupational Therapy)), by Disease Type (Friedreich's Ataxia, Ataxia-telangiectasia, Spinocerebellar Ataxias, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Oct 2021
Code : CMI4714
Pages :150
Formats :
Excel and PDF
Industry : Biotechnology

Leading Companies

Key Players

Major players operating in the global ataxia market include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan

Companies covered:

Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan